Pregabalin abuse among opiate addicted patients

European Journal of Clinical Pharmacology

Volumn 69, Issue 12, 2013, Pages 2021-2025

  Grosshans, Martin ^a   Lemenager, Tagrid ^a   Vollmert, Christian ^a   Kaemmerer, Nina ^a   Schreiner, Rupert ^b   Mutschler, Jochen ^c   Wagner, Xenija ^a   Kiefer, Falk ^a   Hermann, Derik ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b Limbach Laboratory   (Germany)

^c UNIVERSITY HOSPITAL OF PSYCHIATRY   (Switzerland)

Author keywords

Abuse; Mass spectrometry; Opiate replacement therapy; Pregabalin; Urine analysis

Indexed keywords

ALCOHOL; AMPHETAMINE DERIVATIVE; BENZODIAZEPINE DERIVATIVE; BUPRENORPHINE; CANNABIS; METHADONE; OPIATE; PREGABALIN;

ADULT; ALCOHOLISM; ANXIETY DISORDER; ARTICLE; CHRONIC PAIN; CONTROLLED STUDY; DRUG ABUSE; DRUG DETOXIFICATION; DRUG EXCRETION; DRUG HALF LIFE; DRUG URINE LEVEL; FEMALE; GENERALIZED ANXIETY DISORDER; HEROIN DEPENDENCE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; MAJOR CLINICAL STUDY; MALE; MASS SPECTROMETER; MIDDLE AGED; OPIATE ADDICTION; OPIATE SUBSTITUTION TREATMENT; PRESCRIPTION; PRIORITY JOURNAL; URINALYSIS; URINARY EXCRETION; VALIDATION PROCESS; YOUNG ADULT;

ADULT; ANALGESICS; FEMALE; GAMMA-AMINOBUTYRIC ACID; HUMANS; MALE; MIDDLE AGED; OPIATE SUBSTITUTION TREATMENT; SUBSTANCE-RELATED DISORDERS; YOUNG ADULT;

EID: 84892368261     PISSN: 00316970     EISSN: 14321041     Source Type: Journal    
DOI: 10.1007/s00228-013-1578-5     Document Type: Article

References (28)

1. Tassone DM, Boyce E, Guyer J, Nuzum D (2007) Pregabalin: a novel gamma-aminobutyric acid analogue in the treatment of neuropathic pain, partial-onset seizures, and anxiety disorders. Clin Ther 29(1):26-48. doi:10.1016/j.clinthera.2007.01.013
2. Bandelow B, Wedekind D, Leon T (2007) Pregabalin for the treatment of generalized anxiety disorder: a novel pharmacologic intervention. Expert Rev Neurother 7(7):769-781. doi:10.1586/14737175.7.7.769
3. Boomershine CS (2010) Pregabalin for the management of fibromyalgia syndrome. J Pain Res 3:81-88
4. Brodie MJ (2004) Pregabalin as adjunctive therapy for partial seizures. Epilepsia 45(Suppl 6):19-27. doi:10.1111/j.0013-9580.2004. 455004.x
5. Moore RA, Straube S, Wiffen PJ, Derry S, McQuay HJ (2009) Pregabalin for acute and chronic pain in adults. Cochrane Database Syst Rev (3):CD007076. doi:10.1002/14651858.CD007076.pub2
6. Englisch S, Esser A, Enning F, Hohmann S, Schanz H, Zink M (2010) Augmentation with pregabalin in schizophrenia. J Clin Psychopharmacol 30(4):437-440. doi:10.1097/JCP.0b013e3181e5c095
7. Martinotti G, di Nicola M, Frustaci A, Romanelli R, Tedeschi D, Guglielmo R, Guerriero L, Bruschi A, De Filippis R, Pozzi G, Di Giannantonio M, Bria P, Janiri L (2010) Pregabalin, tiapride and lorazepam in alcohol withdrawal syndrome: a multi-centre, randomized, single-blind comparison trial. Addiction 105(2):288-299. doi:10.1111/j.1360-0443.2009.02792.x
8. (2011) The IMS Institute for Healthcare Informatics. http://www.drugs. com/stats/top100/2011/sales. Accessed 28 Dec 2012
9. EMA (2005) European Medicines Agency (EMA). Lyrica (pregabalin) scientific discussion. Available from: http://www.emea.europa.eu/humandocs/ humans/EPAR/lyrica/lyrica.htm
10. Drug Enforcement Administration DoJ (2005) Schedules of controlled substances: placement of pregabalin into schedule V. Fed Regist 70(144):43633-43635
11. Grosshans M, Mutschler J, Hermann D, Klein O, Dressing H, Kiefer F, Mann K (2010) Pregabalin abuse, dependence, and withdrawal: a case report. Am J Psychiatry 167(7):869. doi:10.1176/appi.ajp.2010.09091269
12. Schwan S, Sundstrom A, Stjernberg E, Hallberg E, Hallberg P (2010) A signal for an abuse liability for pregabalin-results from the Swedish spontaneous adverse drug reaction reporting system. Eur J Clin Pharmacol 66(9):947-953. doi:10.1007/s00228-010-0853-y
13. Caster O, Edwards IR, Noren GN, Lindquist M (2011) Earlier discovery of pregabalin's dependence potential might have been possible. Eur J Clin Pharmacol 67(3):319-320. doi:10.1007/s00228-010-0920-4
14. Dyrkorn R, Reimers A, Johannessen L, Spigset O (2011) Do urine tests for drugs of abuse cover the substances of interest? Tidsskr Nor Laegeforen 131(6):570-572. doi:10.4045/tidsskr.10.0368
15. Abuse and Misuse Potential of Pregabalin: A Review of the Clinical Evidence (2012) http://www.cadth.ca/media/pdf/htis/april-2012/ RC0348%20Pregabalin%20draft%20report%20Final.pdf. Accessed 28th december 2012
16. Zacny JP, Paice JA, Coalson DW (2012) Subjective, psychomotor, and physiological effects of pregabalin alone and in combination with oxycodone in healthy volunteers. Pharmacol Biochem Behav 100(3):560-565. doi:10.1016/j.pbb. 2011.10.023
17. Heltsley R, Depriest A, Black DL, Robert T, Caplan YH, Cone EJ (2011) Urine drug testing of chronic pain patients. IV. Prevalence of gabapentin and pregabalin. J Anal Toxicol 35(6):357-359
18. Guay DR (2005) Pregabalin in neuropathic pain: a more "pharmaceutically elegant" gabapentin? Am J Geriatr Pharmacother 3(4):274-287
19. Bockbrader HN, Radulovic LL, Posvar EL, Strand JC, Alvey CW, Busch JA, Randinitis EJ, Corrigan BW, Haig GM, Boyd RA, Wesche DL (2010) Clinical pharmacokinetics of pregabalin in healthy volunteers. J Clin Pharmacol 50(8):941-950. doi:10.1177/0091270009352087
20. Filipetto FA, Zipp CP, Coren JS (2010) Potential for pregabalin abuse or diversion after past drug-seeking behavior. J Am Osteopath Assoc 110(10):605-607
21. Pfizer Inc (2011) Prescribing information: Lyrica. http://www.pfizer.com/ products/product-detail/lyrica. Accessed 28 Dec 2012
22. Kammerer N, Lemenager T, Grosshans M, Kiefer F, Hermann D (2012) Pregabalin for the reduction of opiate withdrawal symptoms. Psychiatr Prax. doi:10.1055/s-0032-1305042
23. Zullino DF, Cottier AC, Besson J (2002) Topiramate in opiate withdrawal. Prog Neuropsychopharmacol Biol Psychiatry 26(6):1221-1223
24. Zullino DF, Krenz S, Zimmerman G, Miozzari A, Rajeswaran R, Kolly S, Khazaal Y (2004) Topiramate in opiate withdrawalcomparison with clonidine and with carbamazepine/mianserin. Subst Abus 25(4):27-33
25. Zullino DF, Krenz S, Favrat B, Zimmermann G, Bertschy G, Besson J (2004) The efficiency of a carbamazepine-mianserin combination scheme in opiate detoxification. Hum Psychopharmacol 19(6):425-430. doi:10.1002/hup.610
26. Di Nicola M, Martinotti G, Tedeschi D, Frustaci A, Mazza M, Sarchiapone M, Pozzi G, Bria P, Janiri L (2010) Pregabalin in outpatient detoxification of subjects with mild-to-moderate alcohol withdrawal syndrome. Hum Psychopharmacol 25(3):268-275. doi:10.1002/hup.1098
27. Martinotti G, Di Nicola M, Tedeschi D, Andreoli S, Reina D, Pomponi M, Mazza M, Romanelli R, Moroni N, De Filippis R, Di Giannantonio M, Pozzi G, Bria P, Janiri L (2010) Pregabalin versus naltrexone in alcohol dependence: a randomised, double-blind, comparison trial. J Psychopharmacol 24(9):1367-1374. doi:10.1177/0269881109102623
28. Bobes J, Rubio G, Teran A, Cervera G, Lopez-Gomez V, Vilardaga I, Perez M (2012) Pregabalin for the discontinuation of long-term benzodiazepines use: an assessment of its effectiveness in daily clinical practice. Eur Psychiatry 27(4):301-307. doi:10.1016/j. eurpsy.2010.12.004